阿尔茨海默病病理生理病理学中的寡类细胞
Shreeya Kedia1,2, Mikael Simons3,4,5,6
1Institute of Neuronal Cell Biology, Technical University Munich, Munich, Germany.
Nature neuroscience
|January 29, 2025
概括
曾经被认为在阿尔茨海默氏症 (AD) 中是被动的寡二细胞,现在已知积极响应粉样蛋白和病理. 这些质细胞在阿尔茨海默氏症的发病过程中发挥着复杂的双重作用,影响疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 质细胞生物学 质细胞生物学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 阿尔茨海默病 (AD) 的理解已经从神经元的重点发展到包括质细胞的参与.
- 虽然AD中的微质细胞,星体细胞和血管细胞得到了很好的研究,但寡聚体细胞的作用仍未得到充分探索.
- 传统上,在阿尔茨海默病中被认为是被动的,但最近的发现表明积极参与.
研究的目的:
- 审查了解阿尔茨海默氏病中寡细胞功能的最新进展.
- 探索阿尔茨海默氏病变发生过程中寡细胞的双重作用.
- 阐明寡细胞,髓囊和AD病理之间的复杂相互作用.
主要方法:
- 关于阿尔茨海默病中寡细胞的最近研究的文献综述.
- 对粉样蛋白和病理学对寡类细胞反应的新兴证据的分析.
- 综合了关于寡头细胞免疫调节,应激反应和生存机制的发现.
主要成果:
- 在阿尔茨海默氏症中,寡二细胞过渡到与疾病相关的状态.
- 它们积极调节免疫反应,并表现出压力和生存机制.
- 有证据表明,寡细胞具有双重作用:潜在的保护性和促进疾病进展.
结论:
- 氧基细胞不是被动的旁观者,而是阿尔茨海默病的积极参与者.
- 它们在免疫调节和对病理反应中的复杂作用需要进一步研究.
- 了解阿尔茨海默病中的寡细胞和髓对于开发新的治疗策略至关重要.
相关概念视频
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Parkinson's Disease: Overview
451
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
451
Glial Cells
86.2K
Overview
86.2K


